Clinical efficacy and safety studies with ELIQUIS did not enroll patients with end-stage renal disease (ESRD) on dialysis.Detailed dosage guidelines and administration information for Eliquis (apixaban).General disorders and administration-site conditions: injection-site hematoma, vessel puncture-site.Thus, administration of activated charcoal may be useful in the management of apixaban overdose or accidental ingestion.
No clinically significant differences in safety or effectiveness were observed when comparing subjects in different age groups.Call us 1-877-900-3784 to buy Eliquis safely and discreetly from CanadaDrugsOnline.com. Guaranteed savings on a wide selection of brand and generic RX drugs. Read.That it might take longer than usual for bleeding to stop, and they may bruise or bleed more easily when treated with ELIQUIS.Learn about Eliquis oral - its uses, dosage, side effects, drug interactions, and safety information on RxList.
Injury, poisoning, and procedural complications: wound hemorrhage, postprocedural hemorrhage.Our Eliquis (apixaban) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.Bleeding results from the AMPLIFY-EXT study are summarized in Table 7.
ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.Effect of Specific Populations on the Pharmacokinetics of Apixaban.Renal and urinary disorders: hematuria (including respective laboratory parameters).In ARISTOTLE, the results for the primary efficacy endpoint were generally consistent across most major subgroups including weight, CHADS 2 score (a scale from 0 to 6 used to predict risk of stroke in patients with AF, with higher scores predicting greater risk), prior warfarin use, level of renal impairment, geographic region, and aspirin use at randomization (Figure 5).Hohnloser and colleagues have now reported the pre-specified subgroup analysis of the ARISTOTLE trial for patients with impaired.Keep a list of them to show your doctor and pharmacist when you get a new medicine.
If you miss a dose of ELIQUIS, take it as soon as you remember.Marketed by: Bristol-Myers Squibb Company Princeton, New Jersey 08543 USA and Pfizer Inc New York, New York 10017 USA.The recommended dose of Eliquis is 5 mg taken orally, twice daily.Eliquis (Apixaban) is an easy to use and effective way to prevent blood clots from forming in your veins.The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information.Copy the URL below and paste it into your RSS Reader application.Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery.Information about potential apixaban side effects and adverse reactions.Do not give ELIQUIS to other people, even if they have the same symptoms that you have.
On-treatment analysis based on the safety population, compared to ITT analysis presented in Section 14.Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding.Monitor patients frequently for signs and symptoms of neurological impairment (e.g., numbness or weakness of the legs, bowel, or bladder dysfunction).
Choosing the Right Blood Thinner for an Irregular Heartbeat Comparing effectiveness, safety, side effects, and price to help you choose the best drug.Treatment duration in both ADVANCE-2 and ADVANCE-1 was 10 to 14 days.
Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in.Events associated with each endpoint were counted once per subject, but subjects may have.Switching from warfarin to ELIQUIS: Warfarin should be discontinued and ELIQUIS started when the international normalized ratio (INR) is below 2.0.In the ADVANCE-3 study, 5407 patients undergoing elective hip replacement surgery were randomized to receive either ELIQUIS 2.5 mg orally twice daily or enoxaparin 40 mg subcutaneously once daily.Hemorrhage (including hematoma, and vaginal and urethral hemorrhage).Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room.The discontinuation rate due to bleeding events was approximately 1% in the ELIQUIS-treated patients compared to 0.4% in those patients in the placebo group in the AMPLIFY-EXT study.
To tell their physicians if they are pregnant or plan to become pregnant or are breastfeeding or intend to breastfeed during treatment with ELIQUIS.Hepatic impairment: Changes in anti-FXa activity were similar in patients with mild-to-moderate hepatic impairment and healthy subjects.